Nanotechnology – Ayurved Healing

Copper Bhasma as Nanomedicine: Particle Size, Efficacy, and Liver Safety

Dr. Meera Iyer — Sat, 19 Sep 2026 09:00:00 +0000

The Science of Tamra Bhasma as Ayurvedic Nanomedicine

Tamra Bhasma is a classical Ayurvedic herbo-metallic preparation made from copper after purification and incineration procedures such as shodhana, bhavana, marana and, in many protocols, amritikarana. Its scientific interest lies in the fact that classical processing can change raw metallic copper into a fine, calcined material with different phase composition, crystallite size, aggregation pattern and elemental profile from the starting metal.

The nanomedicine view of Tamra Bhasma is useful when it is kept precise. Published analytical work does not support treating every product sold as “Tamra Bhasma” as chemically identical. Some characterized samples have matched copper oxide, some have shown copper sulfide phases, and some have shown nanocrystalline domains that exist within larger agglomerates. For this reason, the batch, preparation method and quality-control profile matter as much as the classical name.

Analytical Profile: Particle Size, Phase and Composition

Modern characterization has used tools such as X-ray diffraction, scanning electron microscopy, energy-dispersive X-ray analysis, X-ray photoelectron spectroscopy, infrared or FTIR spectroscopy, thermogravimetry, particle-size distribution and elemental analysis. Together, these tools separate three questions that are often confused: whether the copper is still metallic, what chemical phase the final product contains, and whether the powder contains nanoscale crystallites or larger agglomerated particles.

Analytical Question	Verified Observation	Meaning for Tamra Bhasma Safety
Is the final material raw metallic copper?	Characterized products have been reported as copper oxide or copper sulfide phases rather than simply raw copper metal.	The final product must be judged by phase analysis, not by the word “copper” alone.
Is it truly nanoscale?	One nanocrystalline preparation had crystallite size below 100 nm, with an average crystallite size reported around 88 nm, while SEM showed micrometer-scale agglomerates of nanocrystallites.	“Nano” is best understood as nanocrystalline structure within a processed powder, not necessarily free-floating nanoparticles.
Does composition vary by method?	A standardized sulfur-based preparation was reported as cupric sulfide by XRD, with 58.56 wt% copper and 22.48 wt% sulfur by ICP-AES.	Different classical media and heating protocols can produce different analytical profiles.
Can trace toxic elements be present?	Trace arsenic, lead, mercury and manganese have been reported in a characterized batch, while cadmium and selenium were not detected in that batch.	Batch testing is essential before clinical use, especially for herbo-metallic preparations.

Why the Nanomedicine Lens Matters

The nanocrystalline interpretation helps explain why bhasma is not simply equivalent to a piece of raw metal. Repeated heating, quenching, levigation and incineration can reduce particle or crystallite size, change crystal phase, increase surface area and alter how the material behaves in biological fluids. At the same time, nanoscale structure does not by itself prove safety or therapeutic effect; safety depends on correct preparation, dose, adjuvant, patient selection and monitoring.

For Tamra Bhasma, the most accurate modern language is “processed copper-based bhasma with nanoscale crystallites in some characterized samples.” This is more reliable than broad claims that all Tamra Bhasma particles are uniformly 20–120 nm or that all products have the same copper oxide chemistry.

Hepatotoxicity: The Critical Safety Question

Copper is an essential trace element, but excess copper exposure can injure the liver. Adult nutritional references commonly place the recommended copper intake at 900 mcg per day and the adult upper intake level at 10 mg per day, with liver damage as the critical adverse endpoint for excess intake. Tamra Bhasma is therefore not comparable to casual dietary copper intake; it is a concentrated classical medicine that requires professional selection and supervision.

Available animal safety data place the risk in three linked areas: whether the copper was purified, whether amritikarana was performed, and how high the dose was. In a 45-day rat evaluation, Tamra Bhasma prepared from unpurified copper produced pathological changes even at the therapeutic-equivalent dose, while the product prepared from purified copper remained safe within the tested protocol up to five times the therapeutic-equivalent dose. In a separate 28-day rat comparison, Tamra Bhasma with and without amritikarana produced no signs of toxicity at therapeutic-equivalent and five-times therapeutic-equivalent doses, while ten-times therapeutic-equivalent dosing produced mild toxicity in organs including liver, kidney, heart and thymus; the non-amritikarana sample showed greater toxicity.

The Role of Classical Purification in Reducing Risk

Classical processing is central to the safety discussion. In a documented standard manufacturing procedure, copper pieces were heated to a red-hot stage and quenched repeatedly in media including sesame oil, buttermilk, cow urine, sour gruel and horse gram decoction during samanya shodhana. A further vishesha shodhana step involved processing the already purified copper in cow urine. These steps precede marana and are not optional when Tamra Bhasma is intended for internal use.

Marana then converts the purified copper through incineration and levigation procedures. Some protocols include purified sulfur, kajjali and lemon juice; amritikarana may follow as a post-incineration refinement. The available comparative toxicity work aligns with the classical insistence that ashuddha or improperly processed Tamra is unsafe and that shodhana and amritikarana are risk-reducing steps rather than cosmetic processing.

Therapeutic Applications and Classical Dosing

Tamra Bhasma is described in Ayurvedic literature and related Rasashastra-oriented sources for selected conditions such as udara, pandu, shvasa and amlapitta, and it is also discussed in relation to disorders of the liver and spleen, abdominal pain, loss of appetite and anemia. These indications belong to physician-directed Ayurvedic practice and should not be converted into self-treatment claims.

A cited classical dosing guideline used in toxicology dose conversion gives Tamra Bhasma as 30 mg twice daily, with honey used as the adjuvant in the animal protocol. Other dose ranges in commercial summaries are less reliable unless tied to a specific classical text, formulation and patient context. The safer practical rule is that Tamra Bhasma should be taken only when prescribed by a qualified Ayurvedic physician and only in the dose, duration and anupana selected for the individual.

Practical Quality Checklist for Safe Discussion with a Practitioner

Because products differ, a responsible discussion should include whether the material was prepared from shodhita copper, whether marana and amritikarana were documented, whether the batch passed classical bhasma tests, and whether modern batch testing includes phase identification, particle or crystallite characterization, elemental profile and screening for toxic contaminants. Patients should also ask whether baseline and follow-up liver and kidney function tests are appropriate for their condition and course length.

Unverified, home-prepared, marketplace-grade or unlabeled metallic preparations should not be used internally. Even a properly prepared Tamra Bhasma is still a potent herbo-metallic medicine, not a wellness supplement. It is especially inappropriate for self-use in pregnancy, liver disease, kidney disease, Wilson’s disease, unexplained anemia, children, or anyone taking regular medication unless supervised by qualified clinicians.

Bottom Line

Tamra Bhasma is a legitimate subject for modern nanomedicine-style analysis because some characterized preparations contain nanoscale crystallites and chemically transformed copper phases. The strongest verified safety message is not that copper bhasma is automatically safe, but that correct shodhana, marana, amritikarana, batch testing, dose control and clinical monitoring are essential to reduce risk.

Medical disclaimer: Tamra Bhasma is a metallic Ayurvedic preparation requiring qualified prescription and monitoring. Self-administration of metallic bhasma preparations is not safe or appropriate. Consult a qualified Ayurvedic practitioner and a healthcare provider before using any bhasma, especially if pregnant, nursing, managing liver, kidney, neurological or metabolic disease, or taking medication.

References

Nanotechnology Carriers for Ayurvedic Bhasma: How Ancient Mineral Medicines Achieve Nano-Scale

Dr. Meera Iyer — Sun, 07 Jun 2026 09:00:00 +0000

Modern microscopy has confirmed an important but easily overstated point about Ayurvedic bhasma: some preparations contain nanometre-scale crystallites, while the powder actually swallowed may contain much larger agglomerates. In a 2011 study of two Swarna Bhasma batches, X-ray diffraction estimated gold crystallites at 28–35 nm, but particle-size measurements found mean diameters in the hundreds of nanometres. A 2017 study found crystallites of about 60 nm assembled into irregular aggregates with a mean hydrodynamic diameter of about 4.7 µm. These findings support materials-science study, but they do not prove that every bhasma is a uniform nanoparticle medicine or that nanoscale size establishes clinical efficacy.

What Is Bhasma? The Classical Pharmaceutical Framework

Bhasma is a fine calcined preparation made from specified metals, minerals, shells or other substances through formula-specific procedures described in Rasa Shastra literature and official Ayurvedic formularies. There is no universal recipe; the sequence, liquids, auxiliary substances, heat pattern and endpoint tests depend on the material and cited method.

Shodhana: preliminary processing that may involve heating and quenching, boiling, washing, grinding or treatment with prescribed liquids. Calling it removal of all “toxins” is too broad; it is material-specific purification and pharmaceutical pretreatment.
Bhavana: wet grinding or levigation with a specified juice, decoction or other liquid. It mixes ingredients, reduces coarse particles and prepares the mass for further processing.
Marana and Putapaka: repeated calcination according to the chosen method, often after pellets are enclosed in an earthen sharava-samputa. Modern studies may use a muffle furnace to reproduce a temperature profile. Depending on ingredients and atmosphere, the product may contain elemental metal, oxides, sulfides or mixed phases; the process is not uniformly a reduction reaction.
Amritikarana, where prescribed: some Tamra or Lauha methods include an additional finishing process. It is not mandatory for every bhasma, and evidence does not support calling it a universal organic coating or proven tissue-targeting step.

Classical endpoint examinations include nishchandratva (absence of visible metallic lustre), rekhapurnatva (fineness sufficient to enter finger lines), varitaratva (floating on still water in the prescribed test) and, where relevant, apunarbhava, which examines resistance to reversion toward the original metal. These process checks do not replace modern identity, composition, contamination, particle-distribution and toxicology testing.

What Microscopy and Diffraction Actually Show

Published measurements differ because studies examine different products and techniques. XRD crystallite size, TEM primary-particle size, SEM aggregate size and DLS hydrodynamic diameter are not equivalent. A powder can contain nanoscale crystallites while behaving as micron-scale aggregates in liquid.

Preparation	Verified finding	Qualification
Swarna Bhasma	Gold crystallites of 28–35 nm in two batches; measured particle diameters were much larger.	In-vitro compatibility does not establish efficacy.
Swarna Bhasma	A separate report described globular gold-containing particles averaging about 56–57 nm.	Not generalizable to all products.
Incinerated gold	About 60 nm crystallites formed aggregates averaging about 4.7 µm by DLS.	Cell-culture, preparation-specific evidence.
Laboratory Swarna Bhasma	FE-TEM reported highly crystalline gold structures containing roughly 5–20 nm particles.	Other studies report micron-scale powder particles.
Rajata Bhasma	One sample contained crystalline silver in aggregates around 170–210 nm.	Does not support a universal 2–3 nm value.
Tamra Bhasma	One standardized preparation was mainly cupric sulfide, with 10% below 2 µm.	Chemistry depended on that method.

The defensible conclusion is that bhasma processing can produce complex micro- and nanostructured materials. It is inaccurate to assign one fixed particle size to each named bhasma. Batch variation is a major research and quality-control issue.

Particle Size, Absorption and Bioavailability

Smaller particles can have greater surface area, but absorption depends on aggregation, dissolution, chemical species, protein binding, surface charge, dose, food, vehicle and intestinal physiology. General nanoparticle transport mechanisms cannot be automatically assigned to a bhasma without product-specific experiments.

A small 2018 human pilot study measured trace gold in blood after single sublingual or oral Swarna Bhasma doses and reported different concentration-time patterns with different routes and accompanying media. It did not establish long-term pharmacokinetics, tissue distribution, clinical benefit or safety in disease. In a 2017 cell-culture study, smaller incinerated-gold particles appeared to enter cells through clathrin-dependent endocytosis and larger aggregates through macropinocytosis; oral intestinal passage and organism-level effects remained unresolved.

Lauha Bhasma is traditionally used in iron-containing Ayurvedic formulations, and modern work has characterized iron-oxide phases, but comparative clinical bioavailability and gastrointestinal tolerability require proper human trials.

Herbal Processing and Surface Chemistry

Plant juices, decoctions, oils, milk products and other media can participate in grinding, complexation, oxidation, sulfide formation and transfer of trace constituents. Analytical studies have detected carbon and multiple elements in some samples. This supports research on process-derived surface chemistry.

Terms such as “functionalization,” “zeta-potential control” and “organ targeting” should be used only when measured for the exact preparation. No reliable human evidence shows that a processing liquid directs bhasma particles selectively to the heart, kidney, brain or another organ. Classical indications and modern nanoparticle-targeting mechanisms are different categories of evidence.

Specific Preparations: Current Evidence

Each preparation must be judged as a distinct pharmaceutical material. Traditional indications can guide research, but they do not substitute for verified trials, standardized composition or contemporary diagnosis.

Swarna Bhasma

Swarna Bhasma is a calcined gold preparation used in later Rasa Shastra and Ayurvedic pharmaceutical practice. The 2011 in-vitro study found negligible hemolysis, aggregation, platelet activation and cytotoxicity for its tested batches; the 2017 study found no toxicity in two cultured human cell lines under its conditions. These results are assay- and product-specific.

A randomized study of Swarna Bhasma, honey and ghee in healthy infants reported no significant between-group advantage in IgG over honey and ghee alone during the study period. It is not evidence that Swarna preparations function as vaccines or prevent infection. Pediatric use requires specialist oversight and reliable product quality.

Lauha Bhasma

Lauha Bhasma is an iron-based preparation produced by methods that may include shodhana, Triphala processing, calcination and amritikarana. Structural studies describe iron-oxide phases rather than one universally fixed compound. A 2016 rat study found no major toxicity at therapeutic-equivalent and five-times levels, but biochemical and histopathological alterations appeared at the highest repeated dose. Animal toxicology neither determines an individual dose nor proves superiority to standard oral iron.

Pravala Pishti

Pravala Pishti is a cold-processed coral preparation, not a bhasma produced by repeated incineration. It is made through fine grinding and levigation according to the selected formulary. It should not replace clinically indicated calcium or osteoporosis treatment.

The Safety Question

Safety cannot be inferred from the words “classical,” “purified,” “nano” or “GMP.” Case reports and surveys have documented lead, mercury or arsenic exposure from some Ayurvedic products, including severe liver injury and systemic toxicity. Conversely, controlled animal studies of particular, characterized bhasmas sometimes report acceptable findings at specified doses and harm at higher doses. Both realities must be acknowledged.

Traditional tests help monitor manufacture, while modern evaluation should include authenticated raw materials, validated process records, chemical speciation, assay of intended ingredients, limits for unintended contaminants, microbial quality and batch-specific certificates of analysis. India’s Drugs Rules place Ayurvedic, Siddha and Unani manufacturing under Schedule T GMP requirements intended to ensure authentic raw materials, prescribed processes, quality control and acceptable finished-product quality. GMP is important, but it does not guarantee clinical efficacy or zero risk.

Disclaimer: Never self-prescribe a bhasma or use an unlabelled metallic preparation. Use only a legally manufactured, batch-tested product prescribed by a qualified Ayurvedic physician experienced in Rasa Shastra, and tell your healthcare provider about every medicine and supplement you take. Extra caution and medical review are essential in pregnancy, childhood, kidney or liver disease, anemia of uncertain cause, and when medicines may affect renal, hepatic or blood function. Suspected adverse effects require prompt medical assessment and, when appropriate, blood metal testing.

Where Research Should Go Next

Research should establish reproducible manufacturing protocols, distinguish primary particles from aggregates, identify chemical species and surface constituents, measure dissolution and bioaccessibility, and compare batches from multiple manufacturers. Pharmacokinetic studies must track absorption, distribution and elimination rather than relying on one early blood measurement.

Clinical studies should use authenticated products, adequate controls, prespecified outcomes, transparent adverse-event reporting and independent replication. Until then, microscopy shows that classical processing can create complex materials; it does not prove rejuvenation, cognitive enhancement, organ targeting or superior bioavailability. Rasa Shastra is represented more accurately when analytical findings, classical doctrine and clinical claims remain clearly separated.

References

Nothing in this article diagnoses or treats a medical condition. Use it as educational information and consult a qualified Ayurvedic practitioner or physician before starting herbs, supplements, detoxes, or therapeutic protocols, especially if pregnant, managing a condition, or taking medication.